VZValerii Zakharychev

Valerii Zakharychev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Valerii Zakharychev has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Strategies for selecting and safety of tyrosine kinase inhibitors in chronic myeloid leukemia: cardio-oncological risks, mutation profile, and new allosteric therapy methods

    by П. І. Гордійчук, Д. В. Мельник, М. П. Гордійчук, О. В. Погорєлов, В. Д. Захаричев

    Background. The introduction of tyrosine kinase inhibitors (TKIs) has transformed chronic myeloid leukemia (CML) from a fatal disease into a manageable chronic condition, bringing the life expectancy of patients closer to that of the general population. Cardiovascular (CV) and metabolic complications have become priority issues for clinicians in the treatment of myeloid leukemia. Adenosine triphosphate (ATP)-competitive TKIs, especially those of the second (nilotinib, dasatinib) and third (ponatinib) generations, although they provide the desired molecular responses, are associated with significant off-target toxicity, including arterial occlusive events (AOE), pulmonary hypertension (PH), and metabolic syndrome. However, there is a clinical dilemma that forces a choice between hematological efficacy and CV safety. The goal is to analyze the current evidence base regarding the spectrum and frequency of cardio-metabolic toxicity of ATP-competitive TKIs; evaluate current risk stratification and multidisciplinary monitoring protocols (NCCN, ELN, ESC); and synthesize data on the clinical efficacy and safety of the new allosteric inhibitor STAMP, asciminib, as a potential paradigm shift in CML therapy. Methods. A systematic review of the scientific literature (PRISMA-ScR) was conducted in the PubMed, Scopus, and Web of Science databases (2021–2024), supplemented by an analysis of key clinical guidelines (NCCN, ELN, ESC) from the last decade. Randomized clinical trials (RCTs), large cohort studies (> 50 participants), and systematic reviews were included. The quality of RCTs was assessed using Cochrane RoB 2, and observational studies were assessed using the Newcastle-Ottawa Quality Assessment Scale (NOQAS). Results. Data synthesis confirmed clear toxicity profiles: nilotinib is associated with the highest risk of developing de novo hyperglycemia (IRR 3.15–3.83) and hyperlipidemia (IRR 4.47–5.15), leading to AOE; dasatinib with pulmonary toxicity (pleural effusions, LH); ponatinib with a high risk of AOE (up to 25 %). The 2022 ESC guidelines emphasize the need for formalized baseline CC assessment (including the HFA-ICOS scale) and proactive monitoring (the “ABCDE” approach). The emergence of asciminib, an allosteric inhibitor, is radically changing the therapeutic landscape. The ASCEMBL RCT (3rd line) showed significantly better tolerability of asciminib compared to bosutinib (frequency of discontinuation due to AEs: 7.7 % vs. 26.3 %). The ASC4FIRST RCT (1st line) demonstrated that asciminib outperforms all standard TKIs (SoC) in terms of both efficacy (MMR at 96 weeks: 74.1 % vs. 52.0 %) and safety (half the discontinuation rate, 1 % AOE). Based on these data, the NCCN (2025) included asciminib as a priority option (Category 1) for first-line therapy. In addition, asciminib is the first drug to combine efficacy against the T315I mutation with a favorable SS profile, resolving a key clinical dilemma. Conclusions. CML therapy is undergoing a paradigm shift, with the allosteric inhibitor asciminib becoming the new standard, offering superior efficacy and safety, eliminating the need to compromise between hematologic response and cardiotoxicity. The choice of TKI can no longer be based solely on hematological parameters and requires the mandatory integration of cardio-oncological principles: multidisciplinary risk stratification, proactive monitoring, and aggressive management of concomitant CV and metabolic diseases.

  • Open Access

    Long–term survival of patients after multimodal treatment of stage IIIA(N2) non–small cell lung cancer

    by V. D. Zakharychev, P. I. Hordiychuk, B. O. Borysiuk

    Objective. To determine the overall and recurrence–free survival rates of patients with stage IIIA(N2) non–small cell lung cancer after various multimodal treatment regimens. Materials and methods. A comparative study of different modes of neoadjuvant and adjuvant treatment using radiation therapy and chemotherapy in cases of surgical intervention for stage III A (N2) non–small cell lung cancer was conducted. The effect of neoadjuvant chemoradiotherapy was studied in 43 patients, neoadjuvant chemotherapy in 200 patients, and neoadjuvant chemotherapy followed by surgery and adjuvant radiotherapy in 63 patients. In all patients, neoadjuvant chemotherapy included 4 cycles of cisplatin + docetaxel or carboplatin + paclitaxel. Radiotherapy consisted of daily sessions with a single focal dose of 2 Gy and a total focal dose of up to 50 Gy, followed by radical surgery. The study was conducted at the Department of Lung and Mediastinal Tumors of the National Cancer Institute. Results. From 12 months to the end of the study, the best recurrence–free survival rates were recorded in patients who underwent neoadjuvant chemoradiotherapy. In cases of complete and high morphological response of the tumor to treatment, they lived significantly longer than other patients in this group. Patients with complete morphological response of the tumor to treatment were also the most numerous in this group. Neoadjuvant chemoradiotherapy contributed to a reduction in the number of pneumonectomies in favor of lung resections. The overall five–year survival rate was (30.1± 5.7)%. after neoadjuvant chemoradiotherapy, (12.3± 3.5)% after neoadjuvant chemotherapy, and (6.3± 2.2)% after neoadjuvant chemotherapy with adjuvant radiotherapy. Conclusions. In terms of long–term survival rates in patients with stage IIIA (N2) non–small cell lung cancer, neoadjuvant chemoradiotherapy is superior to other methods of neoadjuvant and adjuvant treatment. Five–year recurrence–free survival rates were demonstrated only in patients who underwent neoadjuvant chemoradiotherapy and amounted to (21.5 ± 6.4)%.

  • Open Access

    EFFICIENCY OF NEOADJUVANT THERAPY OF MALIGNANT TUMORS OF THE MEDIASTINAL AND CHEST WALL

    by Valerii Zakharychev, Prokip Gordiichuk, Mykola Gordiichuk

    Background: Primary tumors of the mediastinum and chest wall are heterogeneous in morphological structure, united only by anatomical localization. Considering their proximity to the vital structures of the mediastinum, their treatment is a complex task that requires a personalized approach in the selection of neoadjuvant therapy. Material and methods: The results of surgical, combined and complex treatment of 1,375 patients with primary malignant tumors of the mediastinum, and 98 patients with malignant tumors of the chest wall were analyzed. Various treatment methods were used in the neoadjuvant regime: radiotherapy, thermoradiotherapy, chemoradiotherapy and intra-arterial regional chemotherapy. Results: The results proved that the use of intra-arterial neoadjuvant chemotherapy (IACT) has a better degree of tumor regression (p0.05) between the variants of neoadjuvant therapy. Conclusions: In the treatment of patients with malignant tumors of the mediastinum and chest wall, the use of neoadjuvant therapy is mandatory. When a malignant tumor is localized in the anterior mediastinum, anterior and side wall of the chest, in the blood circulation zone of a. thoracica interna, a promising variant of neoadjuvant therapy is intra-arterial regional chemotherapy.

  • Open Access

    ГІСТОГЕНЕЗ РАКУ ЛЕГЕНІ - ЕТАПИ ДОСЛІДЖЕННЯ

    by Л. С. Болгова, Т. М. Туганова Т. М. Туганова, О. І. Алексеенко, А. О. Пономаренко, V. D. Zaharichev

    Background. Lung cancer (LC) is the most common malignant tumor in humans. The clinical course of this disease is characterized by late diagnosis, high mortality and poor prognosis. Studing the histogenesis of LC will reveal the features of initial and prolonged growth and explain the mentioned state of the problem. The aim: to determine the histogenesis, features of growth and histological structure of LC. Material and methods. The operative material of 120 patients with LC was studied. Histological preparations stained with hematoxylin and eosin and by the Papanicolaou method were studied. Different levels of proliferative activity of LC cells were determined by a number of morphological features and by immunohistochemical indicators with monoclonal antibodies - Ki67; PCNA. Histological studies were performed at magnifications: X200; X400; X1000. Results. The study of histological preparations of LC, which are most often found in oncology practice - squamous cell (49), glandular (66) and small cell (5), revealed the growth of a cancerous tumor in the alveoli. According to a complex of histological and immunohistochemical indicators, it was determined that the growth of the cancerous tumor started from the basement membrane and grew towards the center of the alveolus. When tumor grown to the center of the alveolus, signs of decay of cancer cells were observed, which separated from the solid part of the tumor and fell into necrotic masses, which are the result of the decay of cancer, which is characteristic of a tumor remote from the blood supply. Conclusions. It has been proven that the main histological types of LC grows in the alveoli and begins from the basal membrane, where the stem cells are located, to the middle of the alveoli. The obtained data are confirmed by the structural, cellular features and the nature of tumor growth in the center of the alveoli, which corresponds to the general patterns of the development of cancer tumors and necrosis with a lack of blood supply.

  • Open Access

    Primary synovial mediastinal sarcomas

    by V. D. Zakharychev, P. І. Gordiichuk, M. P. Gordiichuk

    Primary synovial mediastinal sarcomas